Canaccord cuts target for BioNTech stock to USD 132.00

Published on 10/15/2026 at 19:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BMO kept a Hold rating and USD 105.00 target on October 12, 2026. BioNTech stock costs EUR 80.65, 19.91 percent below its high.

Canaccord target meets valuation pressure

Canaccord cut its BioNTech target from USD 136.00 to USD 132.00 on October 14, 2026.
Second-quarter revenue fell to EUR 106.00 million from EUR 261.00 million in the prior-year quarter.
BioNTech stock costs EUR 80.65 at Lang & Schwarz on October 15, 2026 at 7:00 p.m. CEST, 19.91 percent below the 52-week high.
BioNTech had USD 22.6 billion in market capitalization on October 15, 2026.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

Canaccord Genuity cut its BioNTech target from USD 136.00 to USD 132.00 on October 14, 2026, while keeping a Buy rating, MarketBeat reports. The new target sits 46.23 percent above BioNTech's Nasdaq price of USD 90.27 on October 15, 2026 at 1:03 p.m. ET. BioNTech stock was trading at EUR 80.65 at Lang & Schwarz on October 15, 2026 at 7:00 p.m. CEST, 19.91 percent below its 52-week high of EUR 100.70.

Revenue falls in the second quarter

BioNTech's second-quarter 2026 revenue fell to EUR 106.00 million from EUR 261.00 million in the prior-year quarter, according to the company's earnings-call transcript carried by Yahoo Finance on October 5, 2026. The transcript also gave full-year revenue guidance of EUR 1.60 billion to EUR 1.90 billion. The revenue decline reflects the lower contribution from COVID-19 products and leaves the pipeline and cash position central to the valuation discussion.

Price remains below the yearly high

The euro quote stood 19.91 percent below the 52-week high and EUR 8.00 above the 52-week low of EUR 72.65 on October 15, 2026. On Nasdaq, BioNTech traded at USD 90.27 at 1:03 p.m. ET, compared with USD 88.66 previously, while volume reached 460,323 shares against an average of 1,203,640 shares.

Valuation and analyst views

BioNTech's market capitalization was USD 22.6 billion on October 15, 2026, and its trailing price-to-earnings ratio was negative 11.79. BMO Capital kept a Hold rating and a USD 105.00 target on October 12, 2026, according to Business Insider. The target is 16.31 percent above the Nasdaq price, making the spread between analyst views and the current quotation a key valuation signal.

Comparison with peers

BioNTech SE: P/E negative 11.79, market capitalization USD 22.6 billion.

Moderna, Inc. (Nasdaq, USD): minus 29.81 P/E, market capitalization USD 94.9 billion.

Gilead Sciences, Inc. (Nasdaq, USD): negative 59.60 P/E, market capitalization USD 197.3 billion.

Price and investor perspective

The quotation remains materially below BioNTech's yearly high, while the second-quarter revenue comparison shows why analysts continue to distinguish between near-term earnings pressure and the longer oncology pipeline. The current Nasdaq quotation and the euro price describe the same trading day in different currencies.

BioNTech stock was trading at EUR 80.65 at Lang & Schwarz on October 15, 2026 at 7:00 p.m. CEST, 19.91 percent below the 52-week high of EUR 100.70. The further course of trading is shown by the continuously updated real-time quote of BioNTech stock.